Global Alpha Capital Management Ltd. increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 17.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 735,590 shares of the specialty pharmaceutical company's stock after purchasing an additional 111,040 shares during the period. ANI Pharmaceuticals accounts for about 3.6% of Global Alpha Capital Management Ltd.'s investment portfolio, making the stock its 6th largest holding. Global Alpha Capital Management Ltd. owned 3.38% of ANI Pharmaceuticals worth $49,248,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of ANIP. National Bank of Canada FI acquired a new position in ANI Pharmaceuticals in the first quarter worth about $79,000. GAMMA Investing LLC grew its stake in shares of ANI Pharmaceuticals by 163.8% during the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after purchasing an additional 881 shares during the last quarter. Mesirow Financial Investment Management Inc. acquired a new position in ANI Pharmaceuticals in the first quarter valued at approximately $206,000. Rafferty Asset Management LLC acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at approximately $200,000. Finally, Bridgefront Capital LLC acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at approximately $204,000. Institutional investors own 76.05% of the company's stock.
ANI Pharmaceuticals Trading Up 4.2%
ANIP traded up $3.40 during trading on Monday, reaching $84.88. 1,671,238 shares of the company's stock were exchanged, compared to its average volume of 461,717. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $87.95. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. The stock has a market capitalization of $1.84 billion, a PE ratio of -110.23 and a beta of 0.61. The firm has a fifty day moving average price of $65.65 and a two-hundred day moving average price of $64.08.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The firm had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. During the same period in the previous year, the firm posted $1.02 EPS. The company's revenue for the quarter was up 53.2% compared to the same quarter last year. As a group, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.
Insider Activity at ANI Pharmaceuticals
In related news, insider Christopher Mutz sold 4,000 shares of the business's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total transaction of $241,800.00. Following the transaction, the insider owned 107,317 shares in the company, valued at $6,487,312.65. The trade was a 3.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Ori Gutwerg sold 881 shares of the business's stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total transaction of $52,921.67. Following the transaction, the senior vice president owned 89,897 shares in the company, valued at $5,400,112.79. The trade was a 0.97% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,681 shares of company stock worth $345,222 in the last quarter. Company insiders own 12.70% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on ANIP shares. Guggenheim reaffirmed a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research note on Monday. HC Wainwright boosted their target price on shares of ANI Pharmaceuticals from $84.00 to $93.00 and gave the company a "buy" rating in a research report on Friday. Piper Sandler restated an "overweight" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Friday. Finally, Wall Street Zen cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $84.75.
View Our Latest Stock Report on ANI Pharmaceuticals
About ANI Pharmaceuticals
(
Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
See Also

Before you consider ANI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.
While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.